Renin inhibitory peptides: a study of structural modifications in the peptide backbone.
We studied the peptide backbone modifications that improve the metabolic stability of the resulting peptides and yet retain high inhibitory activity against human plasma renin. A systematic investigation of N-alpha-methyl and C-alpha-methyl modifications at the P2 and P3 sites of renin-inhibitory peptides that contain part of the human angiotensinogen sequence led to the discovery of N-alpha-methyl amino acids at the P2 site as a useful structural modification. U-71,038 (11) inhibited human plasma renin with an in vitro potency (IC50) of 2.6 x 10(-10) mol/l. It is highly selective for renin and, as anticipated, resistant to proteolytic degradation. Additional study based on molecular graphic modelling has led us to propose a gamma-lactam conformational constraint at the P2-P3 site. This pseudo-dipeptide has proved useful in the preparation of active renin inhibitors. Compound 18a inhibited human plasma renin with an in vitro potency (IC50) of 2.1 x 10(-9) mol/l. This class of compounds also offers structural features for the study of enzyme-bound conformers.
Thaisrivongs
S
S
Cardiovascular Diseases Research, Upjohn Company, Kalamazoo, Michigan 49001.
Pals
D T
DT
Turner
S R
SR
Kroll
L T
LT
D000595:Amino Acid Sequence; D000596:Amino Acids; D015195:Drug Design; D006801:Humans; D008745:Methylation; D008969:Molecular Sequence Data; D009842:Oligopeptides / Q000235:genetics; D000092502:Renin Inhibitors
D000596:Amino Acids; D009842:Oligopeptides; D000092502:Renin Inhibitors; C027509:renin inhibitory peptide